Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by INVENTIVA

Inventiva reports 2024 Third Quarter Financial Information¹
From INVENTIVA
Via GlobeNewswire
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
From INVENTIVA
Via GlobeNewswire
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
From INVENTIVA
Via GlobeNewswire
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
From INVENTIVA
Via GlobeNewswire
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
From INVENTIVA
Via GlobeNewswire
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
From INVENTIVA
Via GlobeNewswire
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
From INVENTIVA
Via GlobeNewswire
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
From INVENTIVA
Via GlobeNewswire
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
From INVENTIVA
Via GlobeNewswire
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
From INVENTIVA
Via GlobeNewswire
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
From INVENTIVA
Via GlobeNewswire
Inventiva announces a €20.1 million issuance of royalty certificates
From INVENTIVA
Via GlobeNewswire
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
From INVENTIVA
Via GlobeNewswire
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
From INVENTIVA
Via GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
From INVENTIVA
Via GlobeNewswire
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
From INVENTIVA
Via GlobeNewswire
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
From INVENTIVA
Via GlobeNewswire
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
From INVENTIVA
Via GlobeNewswire
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
From INVENTIVA
Via GlobeNewswire
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
From INVENTIVA
Via GlobeNewswire
Inventiva announces the nomination of Andre Turenne as Director
From INVENTIVA
Via GlobeNewswire
Inventiva reports its 2023 full-year results
From INVENTIVA
Via GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
From INVENTIVA
Via GlobeNewswire
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
From INVENTIVA
Via GlobeNewswire
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
From INVENTIVA
Via GlobeNewswire
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
From INVENTIVA
Via GlobeNewswire
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
From INVENTIVA
Via GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
From INVENTIVA
Via GlobeNewswire
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
From INVENTIVA
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.